S J Done1, S Eskandarian, S Bull, M Redston, I L Andrulis. 1. Department of Laboratory Medicine and Pathobiology and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Abstract
BACKGROUND: To understand the role of sporadic mutations in the tumor suppressor gene p53 (also known as TP53) in the pathogenesis of breast cancer, it is important to identify at which histologic stage such mutations first occur. We previously showed that a p53 mutation present in invasive breast cancer was found in all surrounding areas of ductal carcinoma in situ (DCIS) but not in areas of hyperplasia or normal breast epithelium. In the present investigation, we studied patients with DCIS, but without invasive breast cancer, to determine the spectrum of DCIS types that can harbor a p53 mutation. METHODS: Formalin-fixed, paraffin-embedded tissues from 94 patients with DCIS were evaluated histologically for the predominant cellular architectural pattern, degree of necrosis, and nuclear grade. Each specimen was also assigned an overall histologic grade (with the use of the Van Nuys Prognostic Index pathologic classification). Tissue specimens were stained immunohistochemically with an anti-p53 antibody. Positively stained tissue areas were analyzed for the presence of p53 mutations by single-strand conformation polymorphism and direct sequencing. All statistical tests were two-sided. RESULTS: DCIS from 10 of 94 patients were found to contain p53 missense mutations. All 10 were of a solid or a comedo histologic pattern and contained cells of nuclear grade 2 or 3 (i.e., more abnormal nuclei). The frequency of p53 missense mutations was statistically significantly different among the three overall histologic grade categories (zero [0%] of 49 with low-grade DCIS, one [4.35%] of 23 with intermediate-grade DCIS, and nine [40.9%] of 22 with high-grade DCIS; df = 2 and P<.0001). CONCLUSION: The DCIS types in patients in this series are representative of clinically detected DCIS. Our finding that p53 mutations can occur before the development of invasive breast cancer, particularly in DCIS of high histologic grade, has potentially important implications for prevention and treatment.
BACKGROUND: To understand the role of sporadic mutations in the tumor suppressor gene p53 (also known as TP53) in the pathogenesis of breast cancer, it is important to identify at which histologic stage such mutations first occur. We previously showed that a p53 mutation present in invasive breast cancer was found in all surrounding areas of ductal carcinoma in situ (DCIS) but not in areas of hyperplasia or normal breast epithelium. In the present investigation, we studied patients with DCIS, but without invasive breast cancer, to determine the spectrum of DCIS types that can harbor a p53 mutation. METHODS:Formalin-fixed, paraffin-embedded tissues from 94 patients with DCIS were evaluated histologically for the predominant cellular architectural pattern, degree of necrosis, and nuclear grade. Each specimen was also assigned an overall histologic grade (with the use of the Van Nuys Prognostic Index pathologic classification). Tissue specimens were stained immunohistochemically with an anti-p53 antibody. Positively stained tissue areas were analyzed for the presence of p53 mutations by single-strand conformation polymorphism and direct sequencing. All statistical tests were two-sided. RESULTS: DCIS from 10 of 94 patients were found to contain p53 missense mutations. All 10 were of a solid or a comedo histologic pattern and contained cells of nuclear grade 2 or 3 (i.e., more abnormal nuclei). The frequency of p53 missense mutations was statistically significantly different among the three overall histologic grade categories (zero [0%] of 49 with low-grade DCIS, one [4.35%] of 23 with intermediate-grade DCIS, and nine [40.9%] of 22 with high-grade DCIS; df = 2 and P<.0001). CONCLUSION: The DCIS types in patients in this series are representative of clinically detected DCIS. Our finding that p53 mutations can occur before the development of invasive breast cancer, particularly in DCIS of high histologic grade, has potentially important implications for prevention and treatment.
Authors: Jia-Min B Pang; Peter Savas; Andrew P Fellowes; Gisela Mir Arnau; Tanjina Kader; Ravikiran Vedururu; Chelsee Hewitt; Elena A Takano; David J Byrne; David Yh Choong; Ewan Ka Millar; C Soon Lee; Sandra A O'Toole; Sunil R Lakhani; Margaret C Cummings; G Bruce Mann; Ian G Campbell; Alexander Dobrovic; Sherene Loi; Kylie L Gorringe; Stephen B Fox Journal: Mod Pathol Date: 2017-03-24 Impact factor: 7.842
Authors: Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly Journal: Expert Rev Mol Diagn Date: 2013-03 Impact factor: 5.225
Authors: Heather M Ochs-Balcom; Catalin Marian; Jing Nie; Theodore M Brasky; David S Goerlitz; Maurizio Trevisan; Stephen B Edge; Janet Winston; Deborah L Berry; Bhaskar V Kallakury; Jo L Freudenheim; Peter G Shields Journal: Breast Cancer Res Treat Date: 2015-09-12 Impact factor: 4.872
Authors: Ricardo E Perez; Hong Shen; Lei Duan; Reuben H Kim; Terresa Kim; No-Hee Park; Carl G Maki Journal: J Biol Chem Date: 2016-03-28 Impact factor: 5.157
Authors: Meng-Hua Tao; Pierre Hainaut; Catalin Marian; Jing Nie; Christine Ambrosone; Stephen B Edge; Maurizio Trevisan; Joan Dorn; Peter G Shields; Jo L Freudenheim Journal: Cancer Causes Control Date: 2013-09-26 Impact factor: 2.506
Authors: Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella Journal: J Cell Mol Med Date: 2008-10-16 Impact factor: 5.310
Authors: Aslaug Aa Muggerud; Jo Anders Rønneberg; Fredrik Wärnberg; Johan Botling; Florence Busato; Jovana Jovanovic; Hiroko Solvang; Ida Bukholm; Anne-Lise Børresen-Dale; Vessela N Kristensen; Therese Sørlie; Jörg Tost Journal: Breast Cancer Res Date: 2010-01-07 Impact factor: 6.466